Treatment of Pulmonary Embolism

Introduction to Treatment Guidelines

The European Society of Cardiology recommends initiating anticoagulation immediately with a direct oral anticoagulant (DOAC) for most patients with confirmed pulmonary embolism, specifically rivaroxaban or apixaban as single-drug regimens, which are now preferred over warfarin and low-molecular-weight heparin (LMWH) combinations for eligible patients 1, 2, 3

High-risk PE is characterized by hemodynamic instability with systolic hypotension or cardiogenic shock requiring vasopressors, and the European Heart Journal recommends aggressive intervention, including immediate administration of unfractionated heparin (UFH) intravenously without waiting for diagnostic confirmation 1, 2, 4
Intermediate-risk PE is defined as hemodynamically stable but with right ventricular dysfunction on imaging or elevated cardiac biomarkers, and the European Heart Journal recommends anticoagulation with a DOAC or LMWH 2, 4
Low-risk PE is characterized by hemodynamic stability without RV dysfunction or myocardial injury, and the European Heart Journal recommends anticoagulation with a DOAC or LMWH 2, 4

For hemodynamically unstable patients, the European Heart Journal recommends immediately administering unfractionated heparin (UFH) intravenously without waiting for diagnostic confirmation, with an initial bolus of 80 U/kg IV and a continuous infusion of 18 U/kg/h, adjusted based on aPTT to maintain 1.5-2.5 times control value (46-70 seconds) 1, 5
Systemic thrombolytic therapy is mandatory for all high-risk PE patients unless absolute contraindications exist, according to the European Heart Journal 1, 2, 4

The European Heart Journal recommends using direct oral anticoagulants (DOACs) as the first-line treatment for intermediate and low-risk PE, with rivaroxaban and apixaban being preferred over vitamin K antagonists for all eligible patients 1, 2, 3, 4
For patients who are not suitable for DOACs, the European Heart Journal recommends using LMWH or fondaparinux followed by warfarin, with enoxaparin and tinzaparin being options for LMWH, and fondaparinux being used in a weight-adjusted manner 5

The European Heart Journal recommends using LMWH as the preferred initial and long-term treatment for cancer patients, with dalteparin being an option, and apixaban being an effective alternative 1, 3, 4
For pregnant patients, the European Heart Journal recommends using therapeutic fixed doses of LMWH based on early pregnancy weight, and all pregnant women with suspected or confirmed PE should be reviewed by a consultant and discussed with maternity services prior to discharge 4, 6

The European Heart Journal recommends discontinuing anticoagulation after 3 months for provoked PE, and continuing anticoagulation indefinitely for unprovoked PE or recurrent VTE, and for patients with antiphospholipid antibody syndrome, indefinite anticoagulation with a vitamin K antagonist is mandatory 1, 2, 4

The European Heart Journal recommends never delaying anticoagulation while awaiting diagnostic confirmation in patients with high or intermediate clinical probability, and never stopping parenteral anticoagulation before achieving therapeutic INR for 2 consecutive days when using warfarin 1, 3
The European Heart Journal also recommends avoiding routine use of inferior vena cava filters, only considering them for absolute contraindications to anticoagulation or recurrent PE despite therapeutic anticoagulation, and avoiding aggressive fluid resuscitation in high-risk PE 2, 3, 4